© Reuters.
Contineum Therapeutics (CTNM) has begun the process of applying for an initial public offering (IPO) on the stock market.
The company introduces itself as follows: “We are a clinical trial biopharmaceutical company dedicated to the discovery and development of new orally administered small molecule drugs. These drugs are designed to modulate biological processes linked to specific medical conditions in fields of neurology, inflammation and immunology (N&I), where there is a significant need for new treatments.”
Goldman Sachs & Co (NYSE:), Morgan Stanley (NYSE:), Stifel and RBC Capital Markets will be the lead underwriters for the offering.
This article was produced and translated with the help of artificial intelligence and was reviewed by an editor. For further details, please see our Terms and Conditions.